<DOC>
	<DOCNO>NCT00210002</DOCNO>
	<brief_summary>The purpose study evaluate response rate obtain heterogeneous oncologic population treat chemotherapy , either Darbepoetin alfa classic treatment association Darbepoetin alfa -ferric saccharose systematic supplementation , administer concomitantly chemotherapy .</brief_summary>
	<brief_title>Evaluation Iron Supplementation During Darbepoetin Alfa Treatment Prophylaxis Severe Anaemia Chemo-Induced</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Age ≥ 18 year Wellinformed write consent , sign patient Patient pick solid tumor treatment , whichever localization , without metastasis Patient revealing , chemotherapy , moderate anemia , mean : Men : 9 &lt; Hb &lt; 12 g/dl ; Women : 9 &lt; Hb &lt; 11 g/dl . Patient least four chemotherapy cycle plan ( eight case weekly chemotherapy ) inclusion study Patients life expectancy high three month Patient general condition compatible study 's followup Contraindication Venofer Anemia curative treatment Bloody transfusion previous four week Documented suspect medullary invasion Uncontrolled arterial hypertension Acute bacterial infection Transferrin saturation 's coefficient Pregnancy Ferric salt oral treatment interrupt since less one week Patient bad french language 's comprehension Patient major psychiatric pathology Patient guardianship , trusteeship justice safeguard</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Solid</keyword>
	<keyword>Anemia</keyword>
	<keyword>darbepoetin alfa</keyword>
	<keyword>ferric saccharose</keyword>
	<keyword>Venofer®</keyword>
	<keyword>Aranesp®</keyword>
</DOC>